A RANDOMIZED TRIAL OF INVERMECTIN VERSUS ALBENDAZOLE FOR THE TREATMENT OF CUTANEOUS LARVA MIGRANS

被引：83

作者：

CAUMES, E ^{[1
]}

CARRIERE, J ^{[1
]}

DATRY, A ^{[1
]}

GAXOTTE, P ^{[1
]}

DANIS, M ^{[1
]}

GENTILINI, M ^{[1
]}

机构：

[1] MERCK SHARP & DOHME LTD,F-75008 PARIS,FRANCE

来源：

AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE | 1993年 / 49卷 / 05期

关键词：

D O I：

10.4269/ajtmh.1993.49.641

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

In an open study, we compared the efficacy of single doses of oral ivermectin (12 mg) and oral albendazole (400 mg) for the treatment of cutaneous larva migrans. Twenty-one patients were randomly assigned to receive ivermectin (n = 10) or albendazole (n = 11). All patients who received ivermectin responded and none relapsed (cure rate = 100%). All but one patient in the group receiving albendazole responded, but five relapsed after a mean of 11 days (cure rate = 46%; P = 0.0 1 7). No major adverse effects were observed. We conclude that a single 12-mg dose of ivermectin is more effective than a single 400-mg dose of albendazole for the treatment of cutaneous larva migrans.

引用

页码：641 / 644

页数：4

共 17 条

[1]

BEAVER PAUL C., 1956, EXPTL PARASITOL, V5, P587, DOI 10.1016/0014-4894(56)90032-7

[2] EFFICACY OF IVERMECTIN IN THE THERAPY OF CUTANEOUS LARVA-MIGRANS [J].